References:

A Lifestyle-Based, Functional Health Approach

for Autoimmune Disease

  1. https://autoimmune.org/resource-center/about-autoimmunity/
  2. https://www.autoimmuneinstitute.org/autoimmune-disease-basics/
  3. https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm
  4. https://autoimmune.org/wp-content/uploads/2019/12/1-in-5-Brochure.pdf
  5. Vojdani A, Vojdani E. The Role of Exposomes in the Pathophysiology of Autoimmune Diseases I: Toxic Chemicals and Food. Pathophysiology. 2021 Dec 18;28(4):513-543. doi: 10.3390/pathophysiology28040034. PMID: 35366249; PMCID: PMC8830458
  6. Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, Chan EKL, Miller FW. Increasing Prevalence of Antinuclear Antibodies in the United States. Arthritis Rheumatol. 2020 Jun;72(6):1026-1035. doi: 10.1002/art.41214. Epub 2020 Apr 30. PMID: 32266792; PMCID: PMC7255943.
  7. Khan MF, Wang H. Environmental Exposures and Autoimmune Diseases: Contribution of Gut Microbiome. Front Immunol. 2020 Jan 10;10:3094. doi: 10.3389/fimmu.2019.03094. PMID: 31998327; PMCID: PMC6970196.
  8. Zhao CN, Xu Z, Wu GC, Mao YM, Liu LN, Qian-Wu, Dan YL, Tao SS, Zhang Q, Sam NB, Fan YG, Zou YF, Ye DQ, Pan HF. Emerging role of air pollution in autoimmune diseases. Autoimmun Rev. 2019 Jun;18(6):607-614. doi: 10.1016/j.autrev.2018.12.010. Epub 2019 Apr 5. PMID: 30959217.
  9. Pollard KM, Hultman P, Kono DH. Toxicology of autoimmune diseases. Chem Res Toxicol. 2010 Mar 15;23(3):455-66. doi: 10.1021/tx9003787. PMID: 20078109; PMCID: PMC3076021.
  10. Vojdani A, Pollard KM, Campbell AW. Environmental triggers and autoimmunity. Autoimmune Dis. 2014;2014:798029. doi: 10.1155/2014/798029. Epub 2014 Dec 24. PMID: 25610638; PMCID: PMC4290643.
  11. Khan MF, Wang G. Environmental Agents, Oxidative Stress and Autoimmunity. Curr Opin Toxicol. 2018 Feb;7:22-27. doi: 10.1016/j.cotox.2017.10.012. Epub 2017 Oct 26. PMID: 29532040; PMCID: PMC5844495.
  12. Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020 Jan 31;9:F1000 Faculty Rev-69. doi: 10.12688/f1000research.20510.1. PMID: 32051759; PMCID: PMC6996528.
  13. Charoensappakit A, Sae-Khow K, Leelahavanichkul A. Gut Barrier Damage and Gut Translocation of Pathogen Molecules in Lupus, an Impact of Innate Immunity (Macrophages and Neutrophils) in Autoimmune Disease. Int J Mol Sci. 2022 Jul 26;23(15):8223. doi: 10.3390/ijms23158223. PMID: 35897790; PMCID: PMC9367802.
  14. Ma L, Morel L. Loss of Gut Barrier Integrity In Lupus. Front Immunol. 2022 Jun 20;13:919792. doi: 10.3389/fimmu.2022.919792. PMID: 35795671; PMCID: PMC9250981.
  15. Matei DE, Menon M, Alber DG, Smith AM, Nedjat-Shokouhi B, Fasano A, Magill L, Duhlin A, Bitoun S, Gleizes A, Hacein-Bey-Abina S, Manson JJ, Rosser EC; ABIRISK Consortium, Klein N, Blair PA, Mauri C. Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease. Med (N Y). 2021 Jul 9;2(7):864-883.e9. doi: 10.1016/j.medj.2021.04.013. PMID: 34296202; PMCID: PMC8280953.
  16. Audo R, Sanchez P, Rivière B, Mielle J, Tan J, Lukas C, Macia L, Morel J, Immediato Daien C. Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation which are reversed by inflammation control. Rheumatology (Oxford). 2022 Aug 10:keac454. doi: 10.1093/rheumatology/keac454. Epub ahead of print. PMID: 35947472.
  17. Camara-Lemarroy CR, Metz L, Meddings JB, Sharkey KA, Wee Yong V. The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. Brain. 2018 Jul 1;141(7):1900-1916. doi: 10.1093/brain/awy131. PMID: 29860380; PMCID: PMC6022557.
  18. Buscarinu MC, Fornasiero A, Romano S, Ferraldeschi M, Mechelli R, Reniè R, Morena E, Romano C, Pellicciari G, Landi AC, Salvetti M, Ristori G. The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. Front Immunol. 2019 Aug 28;10:1916. doi: 10.3389/fimmu.2019.01916. PMID: 31555257; PMCID: PMC6724505.
  19. Camara-Lemarroy CR, Metz LM, Yong VW. Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome. World J Gastroenterol. 2018 Oct 7;24(37):4217-4223. doi: 10.3748/wjg.v24.i37.4217. PMID: 30310254; PMCID: PMC6175760.
  20. Cayres LCF, de Salis LVV, Rodrigues GSP, Lengert AVH, Biondi APC, Sargentini LDB, Brisotti JL, Gomes E, de Oliveira GLV. Detection of Alterations in the Gut Microbiota and Intestinal Permeability in Patients with Hashimoto Thyroiditis. Front Immunol. 2021 Mar 5;12:579140. doi: 10.3389/fimmu.2021.579140. PMID: 33746942; PMCID: PMC7973118.
  21. Gong B, Wang C, Meng F, Wang H, Song B, Yang Y, Shan Z. Association Between Gut Microbiota and Autoimmune Thyroid Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021 Nov 17;12:774362. doi: 10.3389/fendo.2021.774362. PMID: 34867823; PMCID: PMC8635774.
  22. Moutsopoulos NM, Moutsopoulos HM. The oral mucosa: A barrier site participating in tissue-specific and systemic immunity. Oral Dis. 2018 Mar;24(1-2):22-25. doi: 10.1111/odi.12729. PMID: 29480644.
  23. Pollard KM, Cauvi DM, Mayeux JM, Toomey CB, Peiss AK, Hultman P, Kono DH. Mechanisms of Environment-Induced Autoimmunity. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:135-157. doi: 10.1146/annurev-pharmtox-031320-111453. Epub 2020 Aug 28. PMID: 32857688; PMCID: PMC8166384.
  24. Sonar SA, Lal G. Blood-brain barrier and its function during inflammation and autoimmunity. J Leukoc Biol. 2018 May;103(5):839-853. doi: 10.1002/JLB.1RU1117-428R. Epub 2018 Feb 12. PMID: 29431873.
  25. Vojdani A, Vojdani E. The Role of Exposomes in the Pathophysiology of Autoimmune Diseases I: Toxic Chemicals and Food. Pathophysiology. 2021 Dec 18;28(4):513-543. doi: 10.3390/pathophysiology28040034. PMID: 35366249; PMCID: PMC8830458.
  26. Vojdani A, Vojdani E, Rosenberg AZ, Shoenfeld Y. The Role of Exposomes in the Pathophysiology of Autoimmune Diseases II: Pathogens. Pathophysiology. 2022 Jun 3;29(2):243-280. doi: 10.3390/pathophysiology29020020. PMID: 35736648; PMCID: PMC9231084.
  27. Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfeld Y. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev. 2013 May;12(7):726-40. doi: 10.1016/j.autrev.2012.12.005. Epub 2012 Dec 22. PMID: 23266520; PMCID: PMC7105216.
  28. Kraft S, Buchenauer L, Polte T. Mold, Mycotoxins and a Dysregulated Immune System: A Combination of Concern? Int J Mol Sci. 2021 Nov 12;22(22):12269. doi: 10.3390/ijms222212269. PMID: 34830149; PMCID: PMC8619365.
  29. Lieberman A, Curtis L. Mold Exposure and Mitochondrial Antibodies. Altern Ther Health Med. 2020 Nov;26(6):44-47. PMID: 32088666.
  30. Tuuminen T, Rinne KS. Severe Sequelae to Mold-Related Illness as Demonstrated in Two Finnish Cohorts. Front Immunol. 2017 Apr 3;8:382. doi: 10.3389/fimmu.2017.00382. PMID: 28421079; PMCID: PMC5377931.
  31. Winzelberg GG, Gore J, Yu D, Vagenakis AG, Braverman LE. Aspergillus flavus as a cause of thyroiditis in an immunosuppressed host. Johns Hopkins Med J. 1979 Mar;144(3):90-3. PMID: 430949.
  32. Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses. 2019 Aug 19;11(8):762. doi: 10.3390/v11080762. PMID: 31430946; PMCID: PMC6723519.
  33. Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfeld Y. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev. 2013 May;12(7):726-40. doi: 10.1016/j.autrev.2012.12.005. Epub 2012 Dec 22. PMID: 23266520; PMCID: PMC7105216.
  34. Dittfeld A, Gwizdek K, Michalski M, Wojnicz R. A possible link between the Epstein-Barr virus infection and autoimmune thyroid disorders. Cent Eur J Immunol. 2016;41(3):297-301. doi: 10.5114/ceji.2016.63130. Epub 2016 Oct 25. PMID: 27833448; PMCID: PMC5099387.
  35. Mahroum N, Elsalti A, Alwani A, Seida I, Alrais M, Seida R, Esirgun SN, Abali T, Kiyak Z, Zoubi M, Shoenfeld Y. The mosaic of autoimmunity – Finally discussing in person. The 13thinternational congress on autoimmunity 2022 (AUTO13) Athens. Autoimmun Rev. 2022 Aug 4;21(10):103166. doi: 10.1016/j.autrev.2022.103166. Epub ahead of print. PMID: 35932955; PMCID: PMC9349027.
  36. Mobasheri L, Nasirpour MH, Masoumi E, Azarnaminy AF, Jafari M, Esmaeili SA. SARS-CoV-2 triggering autoimmune diseases. Cytokine. 2022 Jun;154:155873. doi: 10.1016/j.cyto.2022.155873. Epub 2022 Apr 5. PMID: 35461172; PMCID: PMC8979824.
  37. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021 Apr;20(4):102792. doi: 10.1016/j.autrev.2021.102792. Epub 2021 Feb 19. PMID: 33610751; PMCID: PMC7892316.
  38. Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, Lauritano EC, Roveta A, Tozzoli R, Guaschino R, Bonometti R. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021 May;14(3):898-907. doi: 10.1111/cts.12953. Epub 2021 Jan 21. PMID: 33306235; PMCID: PMC8212749.
  39. Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun Rev. 2020 Dec;19(12):102695. doi: 10.1016/j.autrev.2020.102695. Epub 2020 Oct 28. PMID: 33130000; PMCID: PMC7598743.
  40. https://www.autoimmuneinstitute.org/is-long-covid-a-new-autoimmune-disease/#:~:text=Despite%20the%20growing%20evidence%20that,be%20made%20for%20other%20causes.
  41. Dotan A, David P, Arnheim D, Shoenfeld Y. The autonomic aspects of the post-COVID19 syndrome. Autoimmun Rev. 2022 May;21(5):103071. doi: 10.1016/j.autrev.2022.103071. Epub 2022 Feb 16. PMID: 35182777; PMCID: PMC8848724.
  42. Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, Müller B, Merle U. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis. 2022 Apr 9;74(7):1191-1198. doi: 10.1093/cid/ciab611. PMID: 34223884; PMCID: PMC8394862.
  43. Wostyn P. COVID-19 and chronic fatigue syndrome: Is the worst yet to come? Med Hypotheses. 2021 Jan;146:110469. doi: 10.1016/j.mehy.2020.110469. Epub 2021 Jan 2. PMID: 33401106; PMCID: PMC7836544.
  44. Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus. 2020 May 13;12(5):e8094. doi: 10.7759/cureus.8094. PMID: 32542149; PMCID: PMC7292717.
  45. Kronzer VL, Bridges SL Jr, Davis JM 3rd. Why women have more autoimmune diseases than men: An evolutionary perspective. Evol Appl. 2020 Dec 1;14(3):629-633. doi: 10.1111/eva.13167. PMID: 33767739; PMCID: PMC7980266.
  46. Desai MK, Brinton RD. Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. Front Endocrinol (Lausanne). 2019 Apr 29;10:265. doi: 10.3389/fendo.2019.00265. PMID: 31110493; PMCID: PMC6501433.
  47. Gomez A, Luckey D, Taneja V. The gut microbiome in autoimmunity: Sex matters. Clin Immunol. 2015 Aug;159(2):154-62. doi: 10.1016/j.clim.2015.04.016. Epub 2015 May 6. PMID: 25956531; PMCID: PMC4560596.
  48. Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012 May;38(2-3):J109-19. doi: 10.1016/j.jaut.2011.10.003. Epub 2011 Nov 12. PMID: 22079680.
  49. Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev. 2007 Jun;6(6):366-72. doi: 10.1016/j.autrev.2006.10.001. Epub 2006 Nov 13. PMID: 17537382.
  50. https://autoimmune.org/resource-center/diagnosis-tips/#:~:text=On%20average%2C%20autoimmune%20patients%20see,quickly%20at%20an%20accurate%20diagnosis.
  51. https://autoimmune.org/wp-content/uploads/2017/04/tips_for_auto_diagnosis.pdf
  52. https://www.newswise.com/articles/in-the-age-of-the-affordable-care-act-new-surveys-of-patients-physicians-highlight-challenges-facing-autoimmune-disease-patients
  53. https://www.autoimmuneinstitute.org/which-doctors-diagnose-treat-autoimmune-disease/
  54. https://www.ifm.org/news-insights/ai-treatment-modalities-improve-quality-life-autoimmune-patients/
  55. Blumberg RS, Dittel B, Hafler D, von Herrath M, Nestle FO. Unraveling the autoimmune translational research process layer by layer. Nat Med. 2012;18(1):35-41. doi:10.1038/nm.2632
  56. McCain J. The disease burden of the most common autoimmune diseases. Manag Care. 2016;25(7):28-32.
  57. Li P, Zheng Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol. 2017;8:460. doi:10.3389/fphar.2017.00460
  58. Joensuu J, Huoponen S, Aaltonen KJ, Konttinen YT, Nordström D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10(3):e0119683. doi:10.1371/journal.pone.0119683
  59. Benjamin O, Bansal P, Goyal A, Lappin SL. Disease modifying anti-rheumatic drugs (DMARD). StatPearls. Updated July 4, 2022. Accessed August 15, 2022. https://www.ncbi.nlm.nih.gov/books/NBK507863/
  60. Chandrashekara S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. Indian J Pharmacol. 2012 Nov-Dec;44(6):665-71. doi: 10.4103/0253-7613.103235. PMID: 23248391; PMCID: PMC3523489.